Business leaders often talk about thinking big. But when it comes to nanotech stocks, the future is all about focusing on the small things. In terms of hard numbers, the global nanotech market reached a valuation of $3.69 billion in 2022. By 2030, the ecosystem could be worth $36.85 billion, or a compound annual growth rate (CAGR) of 33.1%. With projected expansion like that, it pays to at least consider these nanotech stocks. To be sure, VECO stock has already enjoyed a robust performance so far this year. ...

Bruker Corporation (BRKR) recently announced the launch of the neofleX Imaging Profiler for mass spectrometry-based tissue imaging at the 72nd ASMS meeting. The novel, high-performance MALDITOF/TOF system enables facile OME-TIFF file output via the new SCiLS Scope software and conveniently fits on a benchtop. The latest development is expected to significantly boost the company's Life Sciences Mass Spectrometry division within the Bruker Scientific Instruments ("BSI") CALID segment. About neofleX The neofle ...

ZURICH, Switzerland and NEWTON, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, has announced the company's attendance at the American Society for Mass Spectrometry (ASMS) Annual Conference from June 2nd to June 6th in Anaheim, CA, where the company will launch Spectronaut 19 and present major scientific and technological advances for its proprietary proteomics research software, services, and data insights solutions. Biogn ...

Bruker Corporation's (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions, and the ongoing portfolio transformation. However, macroeconomic issues dent profit. The stock carries a Zacks Rank #3 (Hold) currently. Bruker's CALID business has been gaining from the strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. Bruker's flagship timsTOF platform is a key dri ...

The Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending, driven by aging demography, and continued innovation in the pharma and life sciences end-markets. Higher demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Industry participants like Mettler-Toledo International (MTD) and Bruker (BRKR) are gaining from the growing testing needs of newer biological drugs. Increased scrutiny of per and polyfluoroalkyl substances i ...

Have you evaluated the performance of Bruker's (BRKR) international operations for the quarter ending March 2024? Given the extensive global presence of this scientific equipment maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must u ...

Equity in Income of Unconsolidated Investees, net of tax Equity in Income of Unconsolidated Investees, net of tax represents the Company's proportional share of the earnings or losses as reported by equity-method investees. Net Income Attributable to Noncontrolling Interests The net income attributable to noncontrolling interests represented the minority shareholders' proportionate share of the net income recorded by our majority-owned subsidiaries. 35 Table of Contents LIQUIDITY AND CAPITAL RESOURCES 31 Op ...

Bruker (BRKR) has been on a downward spiral lately with significant selling pressure. After declining 22.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ...

财务数据和关键指标变化 - 第一季度收入为7.217亿美元,同比增长5.3%,其中有3.8%来自并购贡献 [10] - 第一季度非GAAP毛利率为51.2%,同比下降220个基点,主要受到产品组合、并购和汇率的不利影响 [19] - 第一季度非GAAP营业利润率为14.0%,同比下降630个基点,主要受到同样因素的影响 [20] - 第一季度非GAAP每股收益为0.53美元,同比下降17.2%,主要受到毛利率和营业利润率下降的影响 [21] 各条业务线数据和关键指标变化 - BioSpin业务第一季度收入为1.83亿美元,同比低单位数增长 [11] - CALID业务第一季度收入为2.28亿美元,同比低单位数下降,主要受到部分收入从第一季度推迟至第二季度的影响 [11] - NANO业务第一季度收入为2.40亿美元,同比中teens增长,受益于学术政府、工业和半导体计量市场的强劲需求 [12] - BEST业务第一季度收入同比高teens增长,受益于超导需求和聚变研究项目以及EUV技术的增长 [12] 各个市场数据和关键指标变化 - 美洲地区第一季度有机收入同比中单位数增长 [18] - 欧洲地区第一季度有机收入同比高单位数增长 [18] - 亚太地区第一季度有机收入同比单位数下降,主要受到日本市场疲软的影响 [18] - 整体EMEA地区第一季度收入同比中teens增长 [18] 公司战略和发展方向及行业竞争 - 公司通过一系列并购交易,包括Chemspeed、ELITech和NanoString,补充了公司在后基因组时代的关键技术和能力 [6][9][77][89] - 公司在蛋白质组学、免疫肽组学、糖蛋白组学等领域持续推出新产品和技术,保持技术领先地位 [13][14] - 公司在半导体计量和先进封装领域受益于人工智能浪潮,相关业务保持中teens增长 [12] - 公司未来将专注于整合并购标的,暂时不会进行大规模并购,而是优先偿还债务 [92] 管理层对经营环境和未来前景的评论 - 第一季度收入增长略低于预期,主要受到去年同期的高基数影响,以及部分收入从第一季度推迟至第二季度 [7][8] - 公司预计第二季度有机收入同比中单位数增长,全年有机收入和利润有望实现行业领先的增长 [8][26] - 公司对中国市场保持谨慎乐观,认为中国政府对科技投资的持续重视将为公司带来长期利好 [43][44] - 公司认为近期并购交易将为未来几年带来良好的投资回报率,是实现长期股东价值的关键 [16] 问答环节重要的提问和回答 问题1 **Puneet Souda 提问** 询问第一季度收入推迟至第二季度的原因,以及对第二季度和全年的预期 [31][32] **Frank Laukien 回答** 第一季度有15百万美元收入推迟至第二季度,主要是由于去年同期的高基数以及客户现场准备和发货的时间问题,这并不反映需求下降。公司预计第二季度有机收入同比中单位数增长,全年有机收入和利润有望实现行业领先的增长 [32][33] 问题2 **Patrick Donnelly 提问** 询问中国市场的订单情况和政府刺激计划的影响 [39][40] **Gerald Herman 和 Frank Laukien 回答** 公司对中国政府即将出台的设备升级刺激计划持谨慎乐观态度,预计将在下半年逐步体现在订单中。总体来看,中国政府对科技投资的持续重视将为公司带来长期利好 [43][44][45] 问题3 **Dan Brennan 提问** 询问NanoString并购交易中知识产权纠纷的处理 [76][77] **Frank Laukien 回答** 公司不会对正在进行的诉讼做具体评论,但认为获得NanoString在空间转录组学领域的领先技术是此次交易的关键战略考虑,将大幅提升公司在该领域的地位 [89][90]

Q1 2024 Earnings Presentation May 2, 2024 BRUKER CORPORATION (NASDAQ: BRKR) Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Justin Ward, Senior Director, Investor Relations & Corporate Development Safe Harbor Statement © 2022 Bruker + -Bruker | | Confidential- © 2023 Bruker | | Q1 2024 Business Update Q1 2024 BUSINESS UPDATE Margin Performance Impacted by Tough Comparison, Acquisitions and FX Reconciliations of non-GAAP to GAAP financia ...